Science

DC2415 - Advancing Diabetes Treatment: The Future of GPCR-Targeted Therapies

Speaker(s)

• 

  Jonathan Campbell, PhD

  Associate Professor
  Duke University
  Cary, North Carolina, United States

  Disclosure(s): Altimmune: Advisory Board (Ongoing); Arrowhead Therapeutics: Advisory Board (Ongoing); Boehringer Ingelheim: Advisory Board (Ongoing); Eli Lilly & Company: Grant/Research Support (Ongoing); Merck: Grant/Research Support (Ongoing); Neurocrine: Board Member (Ongoing); novo nordisk: Grant/Research Support (Ongoing); Prostasis: Board Member (Ongoing); Septerna: Advisory Board (Ongoing); Structure Therapeutics: Advisory Board (Ongoing)
• 

  Robert Screaton, PhD (he/him/his)

  Senior Scientist
  Sunnybrook Research Institute
  University of Toronto
  Toronto, Ontario, Canada

  Disclosure(s): I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose

Moderator(s)

• 

  Erin E. Mulvihill, PhD

  Scientist, Primary Investigator
  University of Ottawa Heart Institute
  University of Ottawa/University of Ottawa Heart Institute
  Ottawa, Ontario, Canada

  Disclosure(s): I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose